{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:00:52Z","timestamp":1781334052232,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ygyno.2023.04.018","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T14:44:44Z","timestamp":1683297884000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control"],"prefix":"10.1016","volume":"174","author":[{"given":"Caressa","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Dorigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Litkouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Devereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2023.04.018_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.ygyno.2023.04.018_bb0010","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"issue":"10023","key":"10.1016\/j.ygyno.2023.04.018_bb0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2023.04.018_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study","volume":"92","author":"Keys","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"9213","key":"10.1016\/j.ygyno.2023.04.018_bb0025","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ygyno.2023.04.018_bb0030","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7447","key":"10.1016\/j.ygyno.2023.04.018_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ygyno.2023.04.018_bb0040","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial Cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.018_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.04.018_bb0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0000000000001598","article-title":"Molecularly classified uterine FIGO grade 3 Endometrioid carcinomas show distinctive clinical outcomes but overlapping morphologic features","volume":"45","author":"Joehlin-Price","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.04.018_bb0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 Endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.018_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2023.04.018_bb0065","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.018_bb0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2014.06.010","article-title":"\u03b2-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers","volume":"134","author":"Myers","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.04.018_bb0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.018_bb0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13578-020-00486-0","article-title":"Integrating pathology, chromosomal instability and mutations for risk stratification in early-stage endometrioid endometrial carcinoma","volume":"10","author":"Li","year":"2020","journal-title":"Cell & Biosci."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.018_bb0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/aogs.13740","article-title":"Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence","volume":"99","author":"Imboden","year":"2020","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"6","key":"10.1016\/j.ygyno.2023.04.018_bb0090","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/ijgc-2020-001241","article-title":"Clinical patterns and genomic profiling of recurrent \u2018ultra-low risk\u2019 endometrial cancer","volume":"30","author":"Stasenko","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.018_bb0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00404-021-06385-0","article-title":"Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis","volume":"306","author":"Travaglino","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"issue":"6","key":"10.1016\/j.ygyno.2023.04.018_bb0100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00428-021-03176-5","article-title":"Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma","volume":"479","author":"Ruz-Caracuel","year":"2021","journal-title":"Virchows Arch."},{"issue":"9","key":"10.1016\/j.ygyno.2023.04.018_bb0110","doi-asserted-by":"crossref","first-page":"dju245","DOI":"10.1093\/jnci\/dju245","article-title":"Clinical significance of CTNNB1 mutation and Wnt pathway activation in Endometrioid endometrial carcinoma","volume":"106","author":"Liu","year":"2014","journal-title":"JNCI"},{"key":"10.1016\/j.ygyno.2023.04.018_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2023.04.018_bb0120","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.018_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.ygyno.2023.04.018_bb0130","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1101\/gr.3869505","article-title":"Sequence, annotation, and analysis of synteny between rice chromosome 3 and diverged grass species","volume":"15","author":"Buell","year":"2005","journal-title":"Genome Res."},{"issue":"5","key":"10.1016\/j.ygyno.2023.04.018_bb0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.molonc.2014.03.021","article-title":"Standardized decision support in next generation sequencing reports of somatic cancer variants","volume":"8","author":"Dienstmann","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2023.04.018_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13073-016-0367-z","article-title":"Somatic cancer variant curation and harmonization through consensus minimum variant level data","volume":"8","author":"Ritter","year":"2016","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.ygyno.2023.04.018_bb0145","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","article-title":"Nuclear \u03b2-catenin localization and mutation of the CTNNB1 gene: a context-dependent association","volume":"31","author":"Kim","year":"2018","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2023.04.018_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2021-003340","article-title":"Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival","volume":"32","author":"Kurnit","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2023.04.018_bb0155","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823001890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823001890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:52:01Z","timestamp":1715820721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823001890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":30,"alternative-id":["S0090825823001890"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}